Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396186 | 1.00 | HRH3 (0.73) | HRH3MAPTUSP2TSHRALDH1A1 | |
| SCHEMBL4389078 | 0.99 | HRH3 (0.76) | HRH3MAPTUSP2TSHRALDH1A1 | |
| SCHEMBL4389535 | 0.97 | HRH3 (0.72) | HRH3MAPTUSP2TSHRALDH1A1 | |
| SCHEMBL4393764 | 0.96 | HRH3 (0.74) | HRH3MAPTUSP2TSHRALDH1A1 | |
| SCHEMBL4390589 | 0.96 | HRH3 (0.74) | HRH3MAPTUSP2TSHRALDH1A1 | |
| SCHEMBL4383771 | 0.95 | HRH3 (0.63) | HRH3ALDH1A1POLBTHRBSMN1; SMN2 | |
| SCHEMBL4383854 | 0.92 | HRH3 (0.61) | HRH3ALDH1A1POLBTHRBSMN1; SMN2 | |
| SCHEMBL4383193 | 0.91 | HRH3 (0.60) | HRH3ALDH1A1POLBTHRBSMN1; SMN2 | |
| SCHEMBL4392313 | 0.90 | HRH3 (0.59) | HRH3MAPTTSHRALDH1A1 | |
| SCHEMBL4395364 | 0.90 | HRH3 (0.59) | HRH3MAPTTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | HRH3 452/4885MAPT 4474/4885USP2 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.